Home Blog Page 1618

KuCoin Institutional and CryptoStruct Partner to Advance Institutional Algorithmic Trading Infrastructure

PROVIDENCIALES, Turks and Caicos Islands, Dec. 2, 2025 /PRNewswire/ — KuCoin Institutional, the institutional arm of top crypto exchange KuCoin, is pleased to announce a strategic partnership with CryptoStruct, a professional-grade software provider specializing in algorithmic trading and market-making infrastructure. This collaboration strengthens KuCoin’s institutional technology stack and delivers a seamless, low-latency environment for professional traders to build, test, and scale advanced trading strategies.


Through this partnership, KuCoin and CryptoStruct will jointly provide institutional clients with a professional algorithmic trading platform powered by CryptoStruct’s ultra-low-latency trading engine and fully normalized market data, enabling institutions to deploy sophisticated strategies with microsecond execution precision. Clients will also benefit from streamlined multi-exchange connectivity, gaining secure and efficient access to multiple marketplaces to reduce operational complexity and execution risk while ensuring consistent performance across venues.

To support evaluation and onboarding, prospective users can trial CryptoStruct’s Strategy Development Kit through a risk-free 4-week program, while existing KuCoin Institutional clients receive an exclusive 2-week trial to experience the full product suite before formal integration. In addition, both parties are committed to continuous technical innovation, with ongoing enhancements to latency optimization, infrastructure stability, and overall platform functionality—ensuring institutions can rely on cutting-edge execution capabilities in an increasingly competitive trading landscape.

“By integrating KuCoin’s deep liquidity and institutional brokerage infrastructure with CryptoStruct’s advanced algorithmic trading technology, we are creating a purpose-built environment for professional traders to innovate and scale with confidence,” said Alison, Head of Key Accounts, Kucoin.

“This collaboration enables traders to focus on strategy development and execution while relying on a robust, low-latency infrastructure designed to support institutional growth across the global digital asset markets,” added Iain Clarke Head of Sales, CryptoStruct.

About KuCoin Institutional

KuCoin Institutional is the institutional business arm of KuCoin, dedicated to serving professional investors, funds, and corporate clients with secure, compliant, and efficient digital asset solutions. By integrating advanced trading infrastructure, liquidity access, and institutional-grade custody partnerships, KuCoin Institutional bridges traditional finance with the digital economy.

Learn more at: www.kucoin.com/institution

About CryptoStruct

CryptoStruct delivers professional-grade software solutions for algorithmic traders and market makers, proven in the most demanding production environments worldwide. Our platform provides fully normalized, ultra-low-latency market data, an advanced strategy framework, and a scalable trading engine capable of executing strategies with microsecond precision across virtually the entire global crypto market.

Learn more at: cryptostruct.com

New TayaGel® Modus expands Jungbunzlauer’s texturant portfolio

– A new era in gellan gum innovation delivers crystal-clear gels with very high gel strength, sustainably-

BASEL, Switzerland, Dec. 2, 2025 /PRNewswire/ — Jungbunzlauer, a global leader in high-quality, sustainable ingredients from natural sources, today launched TayaGel® Modus, a gellan gum designed to deliver exceptional clarity and high gel strength in a wide range of applications. This latest addition to the company’s growing texturants portfolio supports label-friendly formulations, creates an elastic, firm and slightly brittle gel and offers new possibilities for formulators seeking a strong vegan alternative to gelatine in desserts.

Developed in line with Jungbunzlauer’s purpose – to create naturally better ingredients that enhance everyday life –TayaGel® Modus meets the growing demand for label-friendly solutions. Its unique functionality offers formulators a versatile solution to meet evolving consumer expectations without compromising on performance.

“TayaGel® Modus further strengthens our texturants offer to customers. This new product provides formulators with a unique gellan gum that delivers an even broader range of customer-preferred textures by combining TayaGel® Modus with TayaGel® HA, TayaGel® LA and our xanthan gum grades” said Jens Birrer, VP Texturants at Jungbunzlauer. “From single ingredients to more complex blends, this innovation reflects our commitment to helping customers with label-friendly solutions for their increasingly complex formulations.”

This represents Jungbunzlauer’s second texturant launch in less than a year, reflecting the company’s focus on supporting customers with trusted, high-quality solutions that simplify formulation challenges and enable greater innovation.

TayaGel® Modus will debut at Fi Europe 2025, taking place 2 – 4 December in Paris, Porte de Versailles (Booth 72Q80). Visitors are invited to sample recipes featuring TayaGel® Modus and other naturally derived ingredients and meet Jungbunzlauer’s experts to discuss application needs and formulation challenges.

For more information about TayaGel® Modus and Jungbunzlauer’s commitment to label-friendly solutions for the food and beverage industry, please visit https://www.jungbunzlauer.com/campaigns/tayagel-modus-2025/ 

About Jungbunzlauer

Jungbunzlauer is a leading producer of high-quality, sustainable ingredients from natural sources, serving industries from food and beverage, to nutrition, health, home and personal care, among others. Leading the way in developing naturally better ingredients that enhance everyday life, we are a trusted partner offering a diverse portfolio of texturants, acidulants, sweeteners, minerals, and tailored solutions to meet our customers’ evolving needs.

Headquartered in Basel, Switzerland, with state-of-the-art facilities including large-scale fermentation operations across Europe and North America, we proudly serve more than 130 countries worldwide. Founded more than 150 years ago, Jungbunzlauer has grown into a CHF 1.3 billion company, driven by nearly 1,400 dedicated colleagues committed to a healthier, more sustainable future. Learn more at www.jungbunzlauer.com.

Logo – https://laotiantimes.com/wp-content/uploads/2025/12/jungbunzlauer_logo.jpg

Neusoft Medical Systems Unveils World’s First 8cm Wide-Coverage Photon-Counting CT and Other Premium Innovations at RSNA 2025

CHICAGO, Dec. 2, 2025 /PRNewswire/ — Neusoft Medical Systems Co., Ltd. (“Neusoft Medical”), a global leader in medical imaging, is showcasing its comprehensive portfolio of intelligent healthcare innovations at the Radiological Society of North America (RSNA) 2025 annual meeting. The highlight of the exhibition is the groundbreaking launch of the NeuViz P10, the world’s first 8cm wide-coverage photon-counting CT. It is joined by several other high-end imaging systems and AI-integrated clinical solutions.

Neusoft Medical booth at RSNA 2025 showcasing its latest imaging innovations.
Neusoft Medical booth at RSNA 2025 showcasing its latest imaging innovations.

The live demonstration presents a full-cycle intelligent imaging ecosystem spanning screening, diagnosis, treatment, rehabilitation, and research – delivering an efficient, connected pathway to improved clinical outcomes.

“We are honored to present advanced technologies that deliver superior imaging performance and intelligent care on this global stage,” said Zhang Dan, Vice President of Neusoft Medical and General Manager of the International Business Center. “From the revolutionary NeuViz P10 photon-counting CT to our comprehensive AI-driven clinical platforms, each innovation is built on deep insights into user needs. We are committed to providing our global partners with tools that enhance workflow efficiency, diagnostic accuracy, and healthcare accessibility.”

Key products featured include:

  • NeuViz P10 Photon-Counting CT: Features an advanced cadmium zinc telluride (CZT) semiconductor detector with 8cm coverage, delivering 50 lp/cm spatial resolution, substantially reduced radiation dose, and precise multi-energy imaging for superior tissue characterization.
  • NeuViz Spire Max+ CT: A high-end 256-slice CT series, incorporates liquid metal bearing technology with large heat capacity and 70kV low-dose scanning, supported by an integrated NeuAI platform that enhances workflow efficiency.
  • NeuMR 3.0T:China’s first comprehensive molecular research MRI, enables molecular metabolic imaging through innovative hardware and AI-integrated reconstruction, advancing precision medicine research.
  • NeuAngio-CT: One-stop multi-modality interventional diagnosis and therapy solutions integrate specialized pathways for chest pain, stroke, trauma, and oncology, streamlining the patient journey from planning through assessment.

Neusoft Medical’s latest high-end systems are gaining rapid global traction, with installations rising worldwide. The company now serves customers in more than 120 countries, with cumulative deployments surpassing 50,000 units. Premium offerings are performing well in developed markets: multiple DSA systems have been installed at leading European medical centers; CT systems are being adopted by private and university hospitals across Eastern Europe and beyond; and MRI products are seeing sequential rollouts. This momentum underscores strong recognition of Neusoft Medical’s technological leadership and product quality among top-tier customers globally.

For more visit: www.neusoftmedical.com/en 

 

Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results

DALLAS, Dec. 2, 2025 /PRNewswire/ — On December 1, Cango Inc. (NYSE: CANG) (“Cango” or the “Company”) announced its unaudited financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Financial and Operational Highlights

  • Total revenues were US$224.6 million in the third quarter of 2025, an increase of 60.6% compared with the second quarter of 2025. Revenue from the bitcoin mining business in the third quarter of 2025 was US$220.9 million.
  • Operating income was US$43.5 million and net income was US$37.3 million over the period. Adjusted EBITDA for the third quarter of 2025 was US$80.1 million.
  • Average operating hashrate increased steadily from 40.91 EH/s in July to 44.85 EH/s in September and further improved to 46.09 EH/s in October, with efficiency surpassing 90%. This was primarily due to mining facility relocations, operational enhancements and miner hardware upgrades.
  • A total of 1,930.8 BTC was mined over the third quarter, averaging 21.0 BTC per day, up 37.5% in total output and 36.0% in daily production compared with the second quarter of 2025. Average cost to mine, excluding depreciation of mining machines, was US$81,072 per BTC, with all-in costs of US$99,383 per BTC. As of the end of September 2025, the Company had mined 5,810 BTC since entering the bitcoin mining industry.
  • The Company completed the termination of its ADR program and transitioned to a direct listing on the NYSE to optimize its capital structure, enhance corporate transparency, and align with its strategic focus.

Mr. Paul Yu, Chief Executive Officer of Cango, said, “This quarter marks a significant milestone. It’s been one year since our strategic transformation into a bitcoin miner. During the third quarter, we remained focused on our core mining operations, further strengthening Cango’s position as a scaled and operationally disciplined bitcoin miner. Specifically, we mined 1,930.8 BTC, averaging 21.0 BTC per day. While consolidating our core business, we also clarified our long-term strategy: building a global, distributed AI compute network powered by green energy, with bitcoin mining as the practical on-ramp toward our energy and compute ambitions. In the near term, we will continue to closely monitor market dynamics, manage our deployed output, and explore partnership models to mitigate market risks and enhance operating stability.”

Full article link: https://ir-image.cangoonline.com/ir-documents/2025-12-2-Cango-Inc-Reports-Third-Quarter-2025-Unaudited-Financial-Results.pdf

Investor Relations Contact
Juliet Ye, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

ATFX Connect Made a Strong Impact and Won The Best B2B Liquidity Provider (Prime of Prime) Award at FMLS:25

LONDON, Dec. 2, 2025 /PRNewswire/ — At the Finance Magnates London Summit 2025 (FMLS:25), ATFX Connect participated in several key institutional panels and was honoured with the Best B2B Liquidity Provider (Prime of Prime) award for its role in delivering liquidity solutions to institutional clients globally. This award stands as a testament to ATFX Connect’s authentic Prime of Prime services, offering efficient access to multiple liquidity sources with flexible solutions tailored for institutional clients.

Among ATFX Connect’s representatives at the event, Wei Qiang Zhang, Managing Director of ATFX Connect Global, was featured on the “Leaders Panel: ‘Thank You, Donald!'”, sharing C-level insights on market volatility, AI integration, and how the industry’s US-dominated role has shifted amid tariffs and changing regulatory landscapes in 2025.

Drew Niv, Chief Strategy Officer of ATFX, spoke on the “All-Star Panel: Next Industry Trends”, covering AI, market structure, and automation shaping 2026. He also participated in the discussion and debate on “Is Prop Trading Good for the Trading Industry?”, sharing ATFX’s views on the funded-account model’s value and regulatory challenges associated with evolving trading frameworks.

On the regional front, Hormoz Faryar, Managing Director of ATFX Connect MEA, provided expert analysis on geopolitical tensions, trade dynamics, and their influence on FX and commodities markets during the “Macro Outlook: Economic Rifts Between Trade Wars & Actual Ones” panel. Joining him, Gonzalo Cañete, Global Chief Market Strategist of ATFX, shared views on global economic cycles, currency flows, and risk factors shaping the trading environment.

ATFX Connect’s presence at FMLS:25, with its award-winning institutional liquidity solutions and strategic expertise, reflects its ongoing commitment to supporting clients worldwide with reliable liquidity services and institutional market insights.

About ATFX Connect

ATFX Connect is a trading name of AT Global Markets (UK) Limited (authorised and regulated by the FCA),  AT Global Markets (Australia) Pty Limited (authorised and regulated by ASIC), and AT Global Financial Services (HK) Limited (authorised and regulated by the SFC). Connect is the Institutional arm of the wider ATFX Group.

ATFX Connect offers Institutional and Professional traders an extensive range of services for both Agency PB and Margin accounts, provides bespoke aggregated liquidity in Spot FX, NDFs, indices, Commodities and Precious metals to a wide range of institutional clients from hedge funds, Tier 1 and regional banks, high net worth investors, asset managers, family offices and other brokers.

ATFX Connect’s liquidity pool is constructed from Tier 1 banks and non-bank providers that it has partnered with, trading in both sweepable and full amount forms.

Agency PB Clients can connect via direct FIX API, external technology solutions or via our own trading platform. For margin clients, ATFX Connect provides market access via the group’s MT4/MT5 platform and provides a bridge solution for those who wish to connect via FIX API.

For further information on ATFX Connect, please visit ATFX Connect website https://www.atfxconnect.com.

PEPSICO® ANNOUNCES LANDMARK GLOBAL PARTNERSHIP WITH MERCEDES-AMG PETRONAS F1 TEAM FOR 2026

Gatorade®, Sting®, and Doritos® unite performance, energy, and flavor with the eight-time FIA World Constructors’ Champions

PURCHASE, N.Y., Dec. 2, 2025 /PRNewswire/ — Today, PepsiCo announces a landmark global partnership with Mercedes-AMG PETRONAS F1 Team beginning in 2026, bringing together three of its powerhouse brands – Gatorade®, Sting®, and Doritos® – with the iconic Formula 1 team. This multi-year partnership builds on PepsiCo’s existing Formula 1 relationship and marks the first time that three category-leading PepsiCo brands will partner with an F1 team.

PEPSICO® ANNOUNCES LANDMARK GLOBAL PARTNERSHIP WITH MERCEDES-AMG PETRONAS F1 TEAM FOR 2026
PEPSICO® ANNOUNCES LANDMARK GLOBAL PARTNERSHIP WITH MERCEDES-AMG PETRONAS F1 TEAM FOR 2026

Building on Formula 1’s explosive growth trajectory and rapidly expanding fanbase, this partnership positions PepsiCo at the heart of the sport’s global momentum through comprehensive integration across Mercedes-AMG PETRONAS F1 Team’s operations, from pioneering hydration programs to immersive fan experiences.

Fueling Team Performance

Gatorade® brings its 60-year heritage and the expertise of the Gatorade Sports Science Institute (GSSI) to the paddock for the first time. In a sport where drivers can lose up to 4 kilograms of body weight through sweat in a single race[1], hydration is critical to performance – and Gatorade’s world-leading expertise in hydration science and performance solutions will be integrated into Mercedes-AMG PETRONAS F1 Team performance programs. This program implements a fully customized performance hydration strategy – giving the Mercedes-AMG PETRONAS F1 Team a performance edge, in a sport where every milliseconds matters.

F1 Talent Meets Brand Power

The partnership will also leverage Mercedes-AMG PETRONAS F1 Team’s drivers, George Russell and Kimi Antonelli, who represent two generations of racing excellence. Russell, established as one of F1’s premier talents, brings proven performance and an authentic connection to fans worldwide. Antonelli, who made headlines with his rapid rise through the ranks to F1, embodies the sport’s exciting future and next generation of talent.

Through the partnership, fans will see both drivers participate in fan engagement initiatives that showcase the collective strengths of Gatorade, Doritos and Sting – from behind-the-scenes content to fan-focused activations.

Energizing the Global Fanbase

Sting®, as the #1 energy drink in markets including India, Pakistan, Vietnam, and Egypt[2], brings its explosive growth story to the paddock. With market-leading positions across emerging markets, Sting’s trajectory mirrors both F1’s and Mercedes-AMG PETRONAS F1 Team’s expansion in these high-growth regions.

Sting brings its energetic brand spirit to race weekends — and with Sting, fast just got faster, connecting Gen Z fans to the Mercedes-AMG PETRONAS F1 Team, bringing them to the race, and delivering the excitement of F1 faster than ever.

Bringing Bold Flavor to the Fast Lane

Doritos® joins the Mercedes-AMG PETRONAS F1 Team to elevate the fan experience with a shared belief in boldness — on the track, in culture, and in every bite. As the world’s boldest snack brand, Doritos will ignite race weekends with high-impact, flavor-forward experiences inspired by the intensity and precision of F1.

Through global activation rights, Doritos will bring its signature edge to fans everywhere, capturing the speed, tension, and excitement of Grand Prix weekends and bringing the thrill of the track into the snacking world. Together, Doritos and Mercedes-AMG PETRONAS F1 Team will provide the global F1 community with an unmistakable combination of flavor and adrenaline.

“This partnership unites performance, energy, and flavor under one banner – connecting three of PepsiCo’s most iconic brands with the world’s most successful Formula 1 team,” said Eugene Willemsen, Chief Executive Officer, International Beverages at PepsiCo. “Through Gatorade, Sting, and Doritos, we’re inside the culture of the sport, fueling both the athletes and the fans who live for the thrill of F 1. Partnering with Mercedes-AMG PETRONAS Formula 1 Team reflects our shared commitment to performance, innovation, and excellence – values that define both our organizations.”

Toto Wolff, Team Principal & Chief Executive Officer, Mercedes-AMG PETRONAS F1 Team, said: “Welcoming a company with a portfolio as strong as PepsiCo’s into our partner ecosystem is another sign of the strength of our team and our sport. As a brand, they align perfectly with our ethos of chasing ultimate performance through innovation and excellence. Gatorade’s expertise in sports science, Sting’s youthful energy, and Doritos’ cultural relevance each bring something unique. Together, they create a partnership that not only supports our team’s performance but also enhances the experience for our fans around the world.”

Richard Sanders, Chief Commercial Officer, Mercedes-AMG PETRONAS F1 Team, said: “We’re delighted to welcome PepsiCo to the team. Their expertise in this sector will help us deliver great experiences for our guests and fans at the track and beyond. It’s a partnership that adds real value to how we operate day-to-day and how we connect with people around the world.”

About PepsiCo 

PepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo generated nearly $92 billion in net revenue in 2024, driven by a complementary drinks and convenient foods portfolio that includes Lay’s, Doritos, Cheetos, Gatorade, Pepsi-Cola, Mountain Dew, Quaker and SodaStream. PepsiCo’s product portfolio includes a wide range of enjoyable foods and drinks, including many iconic brands that generate more than $1 billion each in estimated annual retail sales.

Guiding PepsiCo is our vision to Be the Global Leader in Drinks and Convenient Foods by Winning with pep+ (PepsiCo Positive). pep+ is our strategic end-to-end transformation that places sustainability at the center of our business strategy, seeking to drive growth and build a stronger, more resilient future for PepsiCo and the communities where we operate. For more information, visit www.pepsico.com, and follow on X (Twitter), Instagram, Facebook, and LinkedIn @PepsiCo.

About the Mercedes-AMG PETRONAS F1 Team 

Mercedes was born to race – and we’ve been doing it since 1901. Today, the Mercedes-AMG PETRONAS F1 Team competes at the pinnacle of motorsport: the FIA Formula One World Championship. 

The pioneering spirit of our company founders lives on in our commitment to innovation and performance. As the world’s original automobile manufacturer, Mercedes-Benz has defined the cutting edge of technology for over a century. Today, our F1 team exists to demonstrate the best of the brand’s performance on the global stage. 

Based in Brackley and Brixworth, UK, over 2,000 committed team members work with a singular mission: to win the world championship. From 2014 to 2021, we secured a record eight consecutive Constructors’ Championships, and we are hungry for more. 

Our journey is not just about performance on the track; we also strive to make a positive impact on the world and inspire future generations. We are proud signatories of the Climate Pledge, and we are leading the way in building a more sustainable and inclusive sport. 

For more information, please visit www.mercedesamgf1.com.  

[1] Source: ESPN
[2] Source: Globaldata, Energy Drinks, Volume Share 2024Y. Data accessed 20-Nov-2025Y.

Photo – https://laotiantimes.com/wp-content/uploads/2025/12/pepsico.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/12/pepsico_logo.jpg

 

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as ATG-022 in combination with pembrolizumab and chemotherapy.

CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive (CPS≥1) unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC): ATG-022 in combination with pembrolizumab (A+P); and ATG-022 in combination with pembrolizumab plus the CAPOX chemotherapy regimen (A+P+C). The primary objective of the study is to assess the safety and tolerability of the two combination regimens, while the secondary objectives include evaluating the regimens’ preliminary antitumor activity, assessing ATG-022’s immunogenicity, and characterizing its pharmacokinetic (PK) profile.

Antengene released updated clinical data from the Phase I/II CLINCH study of ATG-022 monotherapy in patients with advanced GC/GEJC at the European Society for Medical Oncology Congress 2025 (ESMO 2025). For details of the dataset, please refer to the press release published on October 20, 2025 (https://www.antengene.com/newsinfo/449). The results demonstrated clear differentiation for ATG-022 in both safety and efficacy. In the 1.8 mg/kg dose cohort, the incidence of grade 3 or higher treatment-related adverse events was only 18.2%. Moreover, the study did not observe any ocular toxicity or interstitial lung disease, and the incidence of peripheral neuropathy reported in the study was relatively low. The efficacious doses (1.8mg/kg and 2.4mg/kg) have both demonstrated an objective response rate (ORR) of 40%. This is a strong validation of ATG-022’s potential in combination with pembrolizumab and chemotherapy in the frontline setting. In addition, antitumor activity was observed across high, medium, and low CLDN18.2 expression levels, supporting the use of IHC 1+ ≥1% as the enrollment threshold for frontline combination therapy, indicating potential applicability to a much broader patient population compared to other CLDN18.2-targeting therapies. Furthermore, in the basket cohort of other CLDN18.2+ tumor types, efficacy was observed in a gynecologic tumor subtype, providing early proof of concept for potential expansion into tumor types beyond gastric cancer.

Antengene will continue to advance both the ongoing CLINCH study and the newly approved CLINCH-2 study, with plans to share updated results at upcoming medical conferences to further demonstrate the clinical potential of ATG-022.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About ATG-022

ATG-022 is a CLDN18.2-targeted antibody-drug conjugate (ADC) with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload (DAR 4), ATG-022 has demonstrated potent activity across tumors with high, low, and ultra-low CLDN18.2 expression.

ATG-022 has been granted two Orphan Drug designations (ODDs) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer, and obtained Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA) for treating CLDN18.2-positive, HER-2 negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received at least two prior lines of therapy.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

“Thermal Control Redefines Quality”: DWMaterials Sets a New Standard in the Electromagnetic Separator Market

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ — DWMaterials is driving a paradigm shift in the electromagnetic separator market with the unveiling of its next-generation de-ironing technology.

Conventional systems have long suffered from issues such as coil damage, magnetic field degradation, and shortened equipment lifespan due to inadequate thermal control. In contrast, DWMaterials’ innovative technology maintains high magnetic force stability while simultaneously improving cooling efficiency, durability, and energy performance.

By integrating accumulated heat-exchange expertise with precise thermal-fluid engineering design, the technology fundamentally resolves heat-related problems and establishes a system that monitors and controls temperature in real time at 18 key points within the de-ironer.

Industry experts in Korea have described the technology as “a redefinition of the industry standard” and noted that it “will become a new benchmark for the electromagnetic separator market.” DWMaterials has already begun sample testing and technical validation with several global customers.